Opaleye Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Opaleye Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-112,500	Closed	-$2.24M	–	43
2024 Q3	$2.24M	Sell	112,500 -527,500	-82%	-$9.78M	0.37%	33
2024 Q2	$9.91M	Sell	640,000 -364,355	-36%	-$5.67M	2.27%	11
2024 Q1	$16M	Sell	1,004,355 -252,845	-20%	-$3.81M	3.49%	6
2023 Q4	$21.4M	Buy	1,257,200 +52,200	+4%	+$714K	5.7%	6
2023 Q3	$14.1M	Buy	+1,205,000	New	+$16.1M	4.58%	6
2020 Q3	–	Sell	-1,155,000	Closed	-$5.34M	–	60
2020 Q2	$5.34M	Buy	1,155,000 +105,000	+10%	+$472K	1.08%	32
2020 Q1	$4.04M	Buy	+1,050,000	New	+$4.31M	1.07%	29
2019 Q2	–	Sell	-1,825,000	Closed	-$9.31M	–	48
2019 Q1	$9.31M	Buy	+1,825,000	New	+$5.36M	2.58%	14
2015 Q1	–	Sell	-975,000	Closed	-$2.9M	–	39
2014 Q4	$2.9M	Hold	975,000	–	–	1.46%	27
2014 Q3	$3.24M	Sell	975,000 -403,584	-29%	-$1.05M	2.52%	17
2014 Q2	$3.49M	Hold	1,378,584	–	–	3.01%	12
2014 Q1	$3.12M	Buy	1,378,584 +24,684	+2%	+$51.6K	2.3%	15
2013 Q4	$2.64M	Buy	+1,353,900	New	+$2.74M	2.07%	15

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Opaleye Management's CPRX Position: Q4 2024 in Review

Opaleye Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 112,500 shares — an estimated $2.24M sold.

Opaleye Management first reported a position in CPRX in Q4 2013 and held it in 13 quarters. The position peaked at $21.4M in Q4 2023. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

Opaleye Management reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
Opaleye Management sold 112,500 Catalyst Pharmaceutical shares in Q4 2024, an estimated $2.24M.
Opaleye Management first reported a position in Catalyst Pharmaceutical in Q4 2013 and held it in 13 quarters.
Opaleye Management's Catalyst Pharmaceutical position peaked at $21.4M in Q4 2023.
336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Opaleye Management's 13F filing for Q4 2024, filed 14 Feb 2025.